Introduction: The process of vascular calcification has severe clinical consequences in a number of diseases, including diabetes, atherosclerosis, and end-stage renal disease. In the present study, we investigated the effect of policosanol (Poli), genistein (Gen), and vitamin D (VitD) separately and in association to evaluate the possible synergistic action on inorganic phosphate (Pi)-induced calcification of vascular smooth muscle cells (VSMCs). Methods: Primary human VSMCs were cultured with either growth medium or growth medium supplemented with calcium and phosphorus (calcification medium) in combination with Poli, Gen, and VitD. Alizarin Red staining, mineralization, and the protein expression of RUNX2 and superoxide dismutase-2 (SOD2) were investigated. Results: All three substances tested were effective at reducing osteogenic differentiation of VSMCs in a dose-dependent manner. Poli+Gen, Poli+VitD, Gen+VitD treatment induced a greater inhibition of calcification and RUNX2 expression compared to single compounds treatments. Moreover, the association of Poli+Gen+VitD (Reduplaxin®) was more effective at inhibiting VSMCs mineralization and preventing the increase in RUNX2 expression induced by calcification medium but not modified SOD2 expression. Conclusions: The association of Pol, Gen, and VitD (Reduplaxin®) has an additive inhibitory effect on the calcification process of VSMCs induced in vitro by a pro-calcifying medium.

In vitro evaluation of the calcification inhibitory properties of Policosanol, Genistein and Vitamin D (Reduplaxin®) either alone or in combination / Iacobini, Carla; Fassino, Valeria; Mazzaferro, Sandro; Tartaglione, Lida. - In: KIDNEY & BLOOD PRESSURE RESEARCH. - ISSN 1420-4096. - 1:49(2024), pp. 137-143. [10.1159/000535810]

In vitro evaluation of the calcification inhibitory properties of Policosanol, Genistein and Vitamin D (Reduplaxin®) either alone or in combination

Carla Iacobini;Valeria Fassino;Sandro Mazzaferro;Lida Tartaglione
2024

Abstract

Introduction: The process of vascular calcification has severe clinical consequences in a number of diseases, including diabetes, atherosclerosis, and end-stage renal disease. In the present study, we investigated the effect of policosanol (Poli), genistein (Gen), and vitamin D (VitD) separately and in association to evaluate the possible synergistic action on inorganic phosphate (Pi)-induced calcification of vascular smooth muscle cells (VSMCs). Methods: Primary human VSMCs were cultured with either growth medium or growth medium supplemented with calcium and phosphorus (calcification medium) in combination with Poli, Gen, and VitD. Alizarin Red staining, mineralization, and the protein expression of RUNX2 and superoxide dismutase-2 (SOD2) were investigated. Results: All three substances tested were effective at reducing osteogenic differentiation of VSMCs in a dose-dependent manner. Poli+Gen, Poli+VitD, Gen+VitD treatment induced a greater inhibition of calcification and RUNX2 expression compared to single compounds treatments. Moreover, the association of Poli+Gen+VitD (Reduplaxin®) was more effective at inhibiting VSMCs mineralization and preventing the increase in RUNX2 expression induced by calcification medium but not modified SOD2 expression. Conclusions: The association of Pol, Gen, and VitD (Reduplaxin®) has an additive inhibitory effect on the calcification process of VSMCs induced in vitro by a pro-calcifying medium.
2024
vascular calcification; vitamin d; policosanol; genistein; vascular smooth muscle cells trans-differentiation
01 Pubblicazione su rivista::01a Articolo in rivista
In vitro evaluation of the calcification inhibitory properties of Policosanol, Genistein and Vitamin D (Reduplaxin®) either alone or in combination / Iacobini, Carla; Fassino, Valeria; Mazzaferro, Sandro; Tartaglione, Lida. - In: KIDNEY & BLOOD PRESSURE RESEARCH. - ISSN 1420-4096. - 1:49(2024), pp. 137-143. [10.1159/000535810]
File allegati a questo prodotto
File Dimensione Formato  
Iacobini_Vitro-evaluation-Calcification_2024.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 529.3 kB
Formato Adobe PDF
529.3 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1705235
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact